Kumsal Bayazit appointed Chief Executive Officer of Elsevier
Amsterdam, January 28, 2019
Elsevier, the information analytics business specializing in science and health, today announced Kumsal Bayazit has been appointed Chief Executive Officer effective February 15, 2019.
Bayazit has worked at RELX Group, Elsevier’s parent company, since 2004. She started her career at Legal and Risk & Business Analytics, where she held a number of senior strategy and operational roles. In 2012, she was appointed Chief Strategy Officer of RELX Group, as well as chair of the company’s Chief Technology Officers’ Forum, formed to foster a strategic acceleration into an increasingly data-driven business focused on analytics and decision tools. For the past three years, she has been the Regional President for Europe, Middle East and Africa at RELX Group’s exhibitions business. Prior to joining RELX Group, Bayazit worked at Bain & Company in the US, South Africa and Australia. She holds an MBA from Harvard Business School and is a graduate of the University of California at Berkeley.
Bayazit replaces Ron Mobed who, after seven years as Elsevier’s Chief Executive Officer, has decided to retire. Mobed joined Elsevier in 2011 and became Chief Executive in 2012. He will support his successor during the transition, providing counsel and advice until June. Youngsuk (YS) Chi will remain Chairman of Elsevier.
About RELX Group
RELX Group is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs about 30,000 people of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £32bn, €37bn, $42bn. www.relx.com
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Hannfried von Hindenburg, SVP Global Communications